Evolent Health Inc (EVH) Price

Biogen Drug News Challenges Revenue Slump

Biogen's stock faces conflicting signals as positive regulatory assessment for its ALS drug, QALSODY, in Canada contrasts with analysis showing significant revenue declines. This sets up a clash between future pipeline potential and current financial performance.

Healthcare Stocks Gain on White House Proposal to Extend ACA Subsidies